Tech Company Financing Transactions
Neurotech Pharmaceuticals Funding Round
Neurotech Pharmaceuticals, based in Lincoln, secured $15.5 million in funding from Apax Partners, Atlas Venture and Merlin BioMed Group.
Transaction Overview
Company Name
Announced On
11/24/2003
Transaction Type
Venture Equity
Amount
$15,500,000
Round
Undisclosed
Investors
Proceeds Purpose
These funds will allow Neurotech to pursue its phase I trial for the treatment of Retinitis Pigmentosa recently initiated at the National Eye Institute and to continue the development of other innovative products for the treatment of retinal diseases that affect the lives of millions of people worldwide.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
900 Highland Corporate Dr. Building 1 101
Lincoln, RI 02864
USA
Lincoln, RI 02864
USA
Phone
Website
Email Address
Overview
Neurotech is a biotechnology company dedicated to the development of sight-saving therapeutics for chronic retinal diseases. Retinal diseases represent significant unmet medical needs for which new medical therapies are the largest market opportunity in ophthalmology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Richard Small
VP - Bus. Development
Konrad Kauper
Browse more venture capital transactions:
Prev: 11/21/2003: Bay Microsystems venture capital transaction
Next: 11/24/2003: Vonage Holdings venture capital transaction
Share this article
News on VC Transactions
We document tech company VC transactions. VC investment data records on this site are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs